SCHEMBL22937443

CNc1nc(Cl)nc2c1ncn2[C@H]1[C@H](OCNc2nc(Cl)nc3c2ncn3[C@H]2[C@H](OCNc3nc(Cl)nc4c3ncn4[C@H]3[C@H](O)[C@H](O)[C@]4(COP(=O)(O)O)C[C@H]34)[C@H](O)[C@]3(COP(=O)(O)OP(=O)(O)O)C[C@H]23)[C@H](O)[C@]2(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)CC[C@H]12

nearest known ligand 0.76

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	P2RY1	P47900	12/20	0.76

▸	P2RY2	P41231	5/20	0.76

▸	ADORA3	P0DMS8	5/20	0.52

▸	HTR2C	P28335	1/20	0.52

▸	HTR2B	P41595	1/20	0.52

▸	P2RY11	Q96G91	1/20	0.50

▸	ADORA1	P30542	1/20	0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL19464972	0.89	P2RY1 (0.85)	P2RY1P2RY2ADORA3HTR2CHTR2B
SCHEMBL24178075	0.88	P2RY1 (0.66)	P2RY1P2RY2ADORA3HTR2CHTR2B
SCHEMBL19807425	0.88	P2RY1 (0.84)	P2RY1P2RY2ADORA3HTR2CHTR2B
SCHEMBL19503293	0.87	P2RY1 (1.00)	P2RY1P2RY2ADORA3HTR2CHTR2B
SCHEMBL29318012	0.87	P2RY1 (0.98)	P2RY1P2RY2ADORA3HTR2CHTR2B
SCHEMBL25613439	0.86	P2RY1 (0.70)	P2RY1P2RY2ADORA3HTR2CHTR2B
SCHEMBL19464926	0.85	P2RY1 (0.72)	P2RY1P2RY2ADORA3HTR2CHTR2B
SCHEMBL29318022	0.84	P2RY1 (0.86)	P2RY1P2RY2ADORA3HTR2CHTR2B
SCHEMBL19807530	0.83	P2RY1 (0.65)	P2RY1P2RY2ADORA3HTR2CHTR2B
SCHEMBL25613499	0.83	P2RY1 (0.67)	P2RY1P2RY2ADORA3HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20210030760-A1	COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS	ASTROCYTE PHARMACEUTICALS, INC.	2021-02-04	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20210030760-A1	COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS	SLC6A3, PNMT, CES2	P2RY1 2266/4885P2RY2 1900/4885ADORA3 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.